TRIAZAVIRIN® for children: Prospects for ARVI therapy discussed at major pediatric conference

Current data on modern approaches to the therapy of acute respiratory viral infections (ARVI) in children were presented at the VI Congress of Children's Physicians of the Moscow Region with international participation «Pediatrics as an Art» (September 3–5, 2025). Zhdanov K. V., Doctor of Medical Sciences, Professor, Director of the Scientific and Clinical Center of the Federal State Budgetary Institution «Federal Scientific and Clinical Center of Infectious Diseases of the Federal Medical and Biological Agency of Russia», corresponding member of the Russian Academy of Sciences, and honored scientist of the Russian Federation, delivered a key report titled «Current Issues of the ARVI Therapy in Children. New Data.»

Special attention in the expert's presentation was given to the direct-acting antiviral drug TRIAZAVIRIN® in a new dosage form for children aged 6–17 years—100 mg. New data obtained from multicenter clinical trials confirm the high efficacy and favorable safety profile of TRIAZAVIRIN® for use in school-age patients. It opens new prospects in the fight against ARVI in children.

Learn more about Triazavirin